Pernix Reinvention Comes Down To Execution

Pernix has a new management team and a budding portfolio of CNS drugs, gained via M&A. Now the company needs to prove it can grow brands that compete in highly genericized markets and drive sustainable growth.

Pernix Therapeutics Holdings Inc. is in the midst of a transformation, led by a new management team that has put together a portfolio of specialty drugs for the treatment of central nervous system disorders.

The company has spent the last 15 months laying the groundwork for its new strategy, acquiring drugs like Treximet (sumatriptan/naproxen)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet